Leo Pharma and MorphoSys Expands Their Existing Collaboration of Antibody-Based Therapies in Dermatology, to Peptide-Derived Therapeutics

 Leo Pharma and MorphoSys Expands Their Existing Collaboration of Antibody-Based Therapies in Dermatology, to Peptide-Derived Therapeutics

Leo Pharma and MorphoSys Expands Their Existing Collaboration of Antibody-Based Therapies in Dermatology, to Peptide-Derived Therapeutics

Shots:

  • Leo Pharma(Leo) will select the targets and MorphoSys will recognize lead molecules using peptide technology platform. Leo Pharma will either develop the lead molecules or use them to design the other drug candidates
  • Leo will have exclusive, worldwide rights and take care of the development and commercialization of any drugs developed in dermatology. MorphoSys will have an option to acquire worldwide rights to any drugs developed in the collaboration in the field of oncology
  • MorphoSys to receive R&D funding with development, regulatory and commercial milestone payments and royalties on net sales of product by Leo Pharma

Click here to read full press release/ article | Ref: LEO Pharma | Image: Pharmaphorum

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post